Center specificity in the limited sampling model (LSM): can the LSM developed from healthy subjects be extended to disease states?
Area under the curve (AUC) can be related to the therapeutic or toxic effect of a drug. In order to accurately measure AUC, multiple blood samples are required, but in a clinical setting, frequent blood sampling from the patients is time-consuming and expensive. The limited sampling model (LSM) is o...
Saved in:
Published in | International journal of clinical pharmacology and therapeutics Vol. 41; no. 11; p. 517 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Germany
01.11.2003
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Area under the curve (AUC) can be related to the therapeutic or toxic effect of a drug. In order to accurately measure AUC, multiple blood samples are required, but in a clinical setting, frequent blood sampling from the patients is time-consuming and expensive. The limited sampling model (LSM) is one of the approaches that is gaining popularity due to its simplicity for the estimation of AUC using 1 - 3 samples. Despite its simplicity, the LSM has some shortcomings. One of the major drawbacks of the LSM is that the LSM developed under a given condition may not be extended to other conditions. For example, the LSM developed from healthy subjects may not be extended to disease states such as renal or hepatic impairment or vice versa. This characteristic of the LSM can be referred to as "center-specific". In this investigation, the LSM developed from the healthy subjects was used to predict AUC in patients with renal or hepatic impairment.
Two sets of simulated plasma concentration versus time data for 2 antihypertensive drugs and measured plasma concentration versus time data for 2 representative drugs (A and B) were used in the analysis.
The results of the study indicate that the LSM developed from healthy subjects is inadequate to predict AUC in patients with hepatic or renal impairment, indicating center specificity of the LSM. |
---|---|
AbstractList | Area under the curve (AUC) can be related to the therapeutic or toxic effect of a drug. In order to accurately measure AUC, multiple blood samples are required, but in a clinical setting, frequent blood sampling from the patients is time-consuming and expensive. The limited sampling model (LSM) is one of the approaches that is gaining popularity due to its simplicity for the estimation of AUC using 1 - 3 samples. Despite its simplicity, the LSM has some shortcomings. One of the major drawbacks of the LSM is that the LSM developed under a given condition may not be extended to other conditions. For example, the LSM developed from healthy subjects may not be extended to disease states such as renal or hepatic impairment or vice versa. This characteristic of the LSM can be referred to as "center-specific". In this investigation, the LSM developed from the healthy subjects was used to predict AUC in patients with renal or hepatic impairment.
Two sets of simulated plasma concentration versus time data for 2 antihypertensive drugs and measured plasma concentration versus time data for 2 representative drugs (A and B) were used in the analysis.
The results of the study indicate that the LSM developed from healthy subjects is inadequate to predict AUC in patients with hepatic or renal impairment, indicating center specificity of the LSM. |
Author | Mahmood, I |
Author_xml | – sequence: 1 givenname: I surname: Mahmood fullname: Mahmood, I email: Mahmoodi@CBER.FDA.GOV organization: Division of Clinical Trial Design & Analysis, Clinical Pharmacology and Toxicology Branch, Center for Biologics Evaluation and Research, FDA, Rockville, MD 20852, USA. Mahmoodi@CBER.FDA.GOV |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/14651035$$D View this record in MEDLINE/PubMed |
BookMark | eNo10EtLxDAUBeAsRpyHgr9A7lIX1SZN0saNSPEFFQfU9ZAmN06Gvmgy4mz95Q6Mrg4HPs7izMmk6zsk5IymV4JTfl0ul5wKmk_ILFVcJlRJMSXzEDZpyoTI1TGZUi4FTTMxIz8ldhFHCAMa77zxcQe-g7hGaHzrI1oIuh0a331C21ts4KJ6e7m8AaMPat_A4hc2_bC3buxbWKNu4noHYVtv0MQANQJ-R-zsXsQerA-oA0KIOmK4PSFHTjcBT_9yQT4e7t_Lp6R6fXwu76rEZKmKSeEyYzhzShjBtJQqLwqZpRK5rjXaOuNZ4ZystVSFVEwhyyRSFAKlKWqWswU5P-wO27pFuxpG3-pxt_o_g_0CMeRgnQ |
CitedBy_id | crossref_primary_10_1002_jcph_1125 crossref_primary_10_2133_dmpk_DMPK_10_RG_077 crossref_primary_10_1007_s00228_011_1136_y crossref_primary_10_1177_0091270005283466 crossref_primary_10_1248_bpb_32_1486 crossref_primary_10_1007_s00228_021_03123_y crossref_primary_10_1007_s00228_012_1437_9 crossref_primary_10_1097_FTD_0000000000001052 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.5414/CPP41517 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 14651035 |
Genre | Clinical Trial Journal Article Comparative Study |
GroupedDBID | --- .GJ 36B 3V. 53G 5GY 7X7 88E 8FI 8FJ ABJNI ABUWG ACGFO ACGFS ADBBV AENEX AFFNX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CGR CUY CVF DLWAR EBS ECM EIF EJD EMB EMOBN F5P FYUFA HMCUK M1P MK0 NPM P2P PQQKQ PROAC PSQYO SJN SV3 UKHRP VDS ZGI ZXP ~4P |
ID | FETCH-LOGICAL-c309t-8f3cc42f95c52a6697886306e4abaedb3438ff6ba6986929e236e1e55e6c8b272 |
ISSN | 0946-1965 |
IngestDate | Sat Sep 28 08:40:08 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c309t-8f3cc42f95c52a6697886306e4abaedb3438ff6ba6986929e236e1e55e6c8b272 |
PMID | 14651035 |
ParticipantIDs | pubmed_primary_14651035 |
PublicationCentury | 2000 |
PublicationDate | 2003-11-01 |
PublicationDateYYYYMMDD | 2003-11-01 |
PublicationDate_xml | – month: 11 year: 2003 text: 2003-11-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | International journal of clinical pharmacology and therapeutics |
PublicationTitleAlternate | Int J Clin Pharmacol Ther |
PublicationYear | 2003 |
References | 16800102 - Int J Clin Pharmacol Ther. 2006 Jun;44(6):292-3; author reply 293-5 |
References_xml | – reference: 16800102 - Int J Clin Pharmacol Ther. 2006 Jun;44(6):292-3; author reply 293-5 |
SSID | ssj0025579 |
Score | 1.7147291 |
Snippet | Area under the curve (AUC) can be related to the therapeutic or toxic effect of a drug. In order to accurately measure AUC, multiple blood samples are... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 517 |
SubjectTerms | Antihypertensive Agents - blood Antihypertensive Agents - pharmacokinetics Area Under Curve Benzimidazoles - blood Benzimidazoles - pharmacokinetics Benzoates - blood Benzoates - pharmacokinetics Blood Specimen Collection - methods Computer Simulation Drug Monitoring - methods Humans Hydrochlorothiazide - blood Hydrochlorothiazide - pharmacokinetics Liver Failure - blood Models, Biological Renal Insufficiency - blood Telmisartan |
Title | Center specificity in the limited sampling model (LSM): can the LSM developed from healthy subjects be extended to disease states? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/14651035 |
Volume | 41 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NbxMxELVSuHBB5buFojmgCpQuZNcf9faCEAIVpKJIpFJv1XozhiK6jZTtIRz7y5lZ2-kmAgRcVontrDaeF2tmMu-NEM-mJvfKIDJjGTPFdTSVlBS4KlmU3uY4DdUWn8zhsfp4ok8Gg6te1dJl617WP37JK_kfq9IY2ZVZsv9g2eVNaYBek33pSham61_ZmFOzrMbMPeRZCaJdpLLF74G3NJxXXDHefAkdb7r-HZ-PKPrnRACff7yWRhJ3ij7R8U0CO3IxnF-6b125h8NhSpeztxr_1hl2dKT5WnHgapKxJ02xZGHOrvWyF6mEM7HAlj7-UfX1PNYDfVjJTchI0uslGZXJWLOwf96qvI-rvHd66kDjXD_VuVM5qwWPx-RtrC6h3Zqdd9bNuan7KEif_Hl2TV87TW2IDYo0uHUq53tiyK51VGuM3yPIF_MDvUqPw7Kz8RZroUnnokw2xe0YW8CbAJQ7YoDNXbE7Dpu92INJb5f3YBfGPTPcE1cBTdBDE5w1QKaBiCZIaIIOTfCckPPiAAhH3Sp6B0scAeMIIo4g4QgcQsIRtBcQcQQBR6_vi-P37yZvD7PYoSOr5ahsM-tlXavCl7rWRWVMuW-toSAUVeUqnDqppPXeuMqU1pAjjoU0mKPWaGrriv3igbjRXDT4SICtpHcei9znVlHQ73KspcZRhbVWTtst8TDs7eksyLCcpl3f_u3MY3HrGpVPxE1Pv3vcISeydU87O_8EYpZz4A |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Center+specificity+in+the+limited+sampling+model+%28LSM%29%3A+can+the+LSM+developed+from+healthy+subjects+be+extended+to+disease+states%3F&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=Mahmood%2C+I&rft.date=2003-11-01&rft.issn=0946-1965&rft.volume=41&rft.issue=11&rft.spage=517&rft_id=info:doi/10.5414%2FCPP41517&rft_id=info%3Apmid%2F14651035&rft_id=info%3Apmid%2F14651035&rft.externalDocID=14651035 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon |